Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Dr Reddys Laboratories Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (303)
ARTG (234)
Prescription medicine registration (15)

Date

2024 (31)
2023 (161)
2022 (28)
2021 (55)
2020 (48)
2019 (26)
2018 (52)
2017 (35)
2016 (78)
2014 (2)
2013 (9)
2012 (16)
2011 (2)
2010 (9)

Results for "[search-keyword]"

Search

Sponsor content

552 result(s) found, displaying 71 to 80

TELCARDIS HCTZ 80/25 telmisartan and hydrochlorothiazide 80/25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
TELMISARTAN HCTZ-DRLA 40/12.5 telmisartan and hydrochlorothiazide 40/12.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
TELCARDEN HCT 40/12.5 telmisartan and hydrochlorothiazide 40/12.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
TELCARDEN HCT 80/25 telmisartan and hydrochlorothiazide 80/25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
TELMISARTAN HCTZ-RZ 40/12.5 telmisartan and hydrochlorothiazide 40/12.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
TELMISARTAN HCTZ-RZ 80/25 telmisartan and hydrochlorothiazide 80/25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
TELMISARTAN HCTZ-DRLA 80/25 telmisartan and hydrochlorothiazide 80/25 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
XELOCITABINE capecitabine 500 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
XELOCITABINE capecitabine 150 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd
RUMICAM meloxicam 15 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

30 March 2023

Cancellation by sponsor

Requested by Dr Reddys Laboratories Australia Pty Ltd

Pages

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.